Novartis: winds down Aduro's lead molecule in portfolio

(CercleFinance.com) - Novartis has decided to remove Aduro's lead molecule from its portfolio based on clinical data to date, the US biotech firm said on Tuesday.


This means that Novartis has begun winding down the ongoing Phase 1b clinical trial to evaluate the safety and preliminary efficacy of ADU-S100 in combination with Novartis' investigational anti-PD-1 monoclonal antibody in solid tumors or lymphomas.

Enrollment in this Phase 1b trial will hence be discontinued.

Novartis is also terminating enrollment of the ongoing Phase 1 clinical trial arm evaluating ADU-S100 in relapsed and refractory melanoma in combination with Yervoy, Bristol-Myers Squibb's approved antibody.

Under the deal with Novartis, Aduro is continuing to enroll the Phase 2 clinical trial of ADU-S100 in combination with Merck's Keytruda as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.

Aduro shares tumbled over 13% on these announcements on the Nasdaq yesterday.

Copyright (c) 2019 CercleFinance.com. All rights reserved.